Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affinergy teams with Synthes

This article was originally published in The Gray Sheet

Executive Summary

"Biological glue" proprietor Affinergy and orthopedic device manker Synthes will collaborate on multiple product applications across the spine, trauma and craniomaxillofacial markets under a long-term development program announced Sept. 11. Affinergy's Interfacial Biomaterial coating process can reduce the risks of infection, friction and clotting associated with an orthopedic implant, and "provide for a much tighter integration of the actual device," the company says (1"The Gray Sheet" March 8, 2004, p. 26). The firm is interested in targeting the cardiovascular market as well...

You may also be interested in...



Affinergy Exploring BMP Applications For IFBM Device Coating Process

Affinergy's plan to license its Interfacial Biomaterial (IFBM) coating process will allow the start-up to avoid the costs of bringing a combination product to market

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel